Asset Details
Do you wish to reserve the book?
A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer
Do you wish to request the book?
A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer
2014
Overview
Purpose
S-1 chemotherapy is effective against advanced biliary tract cancer. The purpose was to evaluate the efficacy and safety of S-1-based concurrent chemoradiotherapy in patients with advanced biliary tract cancer.
Methods
Patients with pathologically-proven advanced biliary tract cancer were eligible. S-1 was orally administered at a dose of 40 mg/m
2
, twice daily from day 1 to 14 and from day 22 to 35; concurrent radiotherapy of 180–200 cGy per fraction was delivered in 25–28 fractions. After treatment completion, tumor response was evaluated by computed tomography. In the first stage of the optimal two-stage phase II design, 18 patients were required.
Results
Twenty patients were enrolled between August 2006 and February 2009. The median age was 62.5 years (range 45–77 years). The median follow-up time was 11.6 months (range 1.9–49.1 months). Fifteen patients (75 %) had extrahepatic cholangiocarcinoma, two patients (10 %) had intrahepatic cholangiocarcinoma, and three patients (15 %) had gallbladder cancer. After treatment, a partial response was achieved in three patients (15 %), and stable disease was achieved in 14 patients (70 %). The overall response rate was 15 %, and the disease stabilization rate was 85 %. There was no grade 4 toxicity or treatment-related death. The common grade 3 toxicities were thrombocytopenia (15 %), neutropenia (10 %), and nausea (10 %). The median progression-free survival and median overall survival were 5.9 months (range 2.2–9.5 months) and 10.8 months (range 1.1–20.4 months), respectively.
Conclusions
This study shows that S-1-based concurrent chemoradiotherapy is feasible and tolerable in patients with advanced biliary tract cancer. It will be further confirmed in a following large-scale phase II study.
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - adverse effects
/ Biliary Tract Neoplasms - drug therapy
/ Biliary Tract Neoplasms - pathology
/ Biological and medical sciences
/ Drug Screening Assays, Antitumor
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Liver. Biliary tract. Portal circulation. Exocrine pancreas
/ Male
/ Medicine
/ Oncology
/ Oxonic Acid - administration & dosage
/ Oxonic Acid - adverse effects
/ Pharmacology. Drug treatments
/ Tegafur - administration & dosage
/ Tumors
